![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ANKRD1 |
Gene summary for ANKRD1 |
![]() |
Gene information | Species | Human | Gene symbol | ANKRD1 | Gene ID | 27063 |
Gene name | ankyrin repeat domain 1 | |
Gene Alias | ALRP | |
Cytomap | 10q23.31 | |
Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | Q15327 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
27063 | ANKRD1 | HCC2 | Human | Liver | HCC | 2.61e-10 | 6.28e+00 | 0.5341 |
27063 | ANKRD1 | Pt13.b | Human | Liver | HCC | 4.60e-12 | 4.61e-01 | 0.0251 |
27063 | ANKRD1 | S028 | Human | Liver | HCC | 1.18e-08 | 8.34e-01 | 0.2503 |
27063 | ANKRD1 | S029 | Human | Liver | HCC | 2.71e-05 | 6.83e-01 | 0.2581 |
27063 | ANKRD1 | ATC11 | Human | Thyroid | ATC | 3.71e-05 | 2.00e+00 | 0.3386 |
27063 | ANKRD1 | ATC2 | Human | Thyroid | ATC | 2.02e-16 | 2.27e+00 | 0.34 |
27063 | ANKRD1 | ATC3 | Human | Thyroid | ATC | 4.34e-11 | 1.96e+00 | 0.338 |
Page: 1 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00321035 | Cervix | CC | positive regulation of response to external stimulus | 95/2311 | 427/18723 | 5.44e-09 | 5.03e-07 | 95 |
GO:00027644 | Cervix | CC | immune response-regulating signaling pathway | 97/2311 | 468/18723 | 1.49e-07 | 7.07e-06 | 97 |
GO:00447725 | Cervix | CC | mitotic cell cycle phase transition | 89/2311 | 424/18723 | 2.70e-07 | 1.12e-05 | 89 |
GO:00305229 | Cervix | CC | intracellular receptor signaling pathway | 60/2311 | 265/18723 | 1.89e-06 | 5.97e-05 | 60 |
GO:20000453 | Cervix | CC | regulation of G1/S transition of mitotic cell cycle | 37/2311 | 142/18723 | 6.33e-06 | 1.53e-04 | 37 |
GO:00457876 | Cervix | CC | positive regulation of cell cycle | 66/2311 | 313/18723 | 7.78e-06 | 1.81e-04 | 66 |
GO:00000824 | Cervix | CC | G1/S transition of mitotic cell cycle | 49/2311 | 214/18723 | 1.16e-05 | 2.48e-04 | 49 |
GO:19028062 | Cervix | CC | regulation of cell cycle G1/S phase transition | 41/2311 | 168/18723 | 1.18e-05 | 2.51e-04 | 41 |
GO:00073466 | Cervix | CC | regulation of mitotic cell cycle | 88/2311 | 457/18723 | 1.26e-05 | 2.60e-04 | 88 |
GO:19019903 | Cervix | CC | regulation of mitotic cell cycle phase transition | 63/2311 | 299/18723 | 1.27e-05 | 2.60e-04 | 63 |
GO:00448434 | Cervix | CC | cell cycle G1/S phase transition | 53/2311 | 241/18723 | 1.76e-05 | 3.32e-04 | 53 |
GO:00028315 | Cervix | CC | regulation of response to biotic stimulus | 67/2311 | 327/18723 | 1.79e-05 | 3.36e-04 | 67 |
GO:00459316 | Cervix | CC | positive regulation of mitotic cell cycle | 32/2311 | 121/18723 | 1.88e-05 | 3.47e-04 | 32 |
GO:00096158 | Cervix | CC | response to virus | 73/2311 | 367/18723 | 2.22e-05 | 3.95e-04 | 73 |
GO:19019922 | Cervix | CC | positive regulation of mitotic cell cycle phase transition | 26/2311 | 93/18723 | 3.97e-05 | 6.18e-04 | 26 |
GO:00431228 | Cervix | CC | regulation of I-kappaB kinase/NF-kappaB signaling | 53/2311 | 249/18723 | 4.50e-05 | 6.87e-04 | 53 |
GO:00900685 | Cervix | CC | positive regulation of cell cycle process | 50/2311 | 236/18723 | 8.25e-05 | 1.11e-03 | 50 |
GO:19019873 | Cervix | CC | regulation of cell cycle phase transition | 74/2311 | 390/18723 | 9.80e-05 | 1.27e-03 | 74 |
GO:00022212 | Cervix | CC | pattern recognition receptor signaling pathway | 39/2311 | 172/18723 | 1.08e-04 | 1.38e-03 | 39 |
GO:00622073 | Cervix | CC | regulation of pattern recognition receptor signaling pathway | 27/2311 | 105/18723 | 1.37e-04 | 1.68e-03 | 27 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ANKRD1 | SNV | Missense_Mutation | c.552N>C | p.Met184Ile | p.M184I | Q15327 | protein_coding | deleterious(0.04) | possibly_damaging(0.898) | TCGA-50-6594-01 | Lung | lung adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD | |
ANKRD1 | SNV | Missense_Mutation | c.347N>A | p.Thr116Lys | p.T116K | Q15327 | protein_coding | tolerated(0.93) | benign(0.166) | TCGA-64-5775-01 | Lung | lung adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | carboplatin | PD | |
ANKRD1 | SNV | Missense_Mutation | c.116N>C | p.Leu39Ser | p.L39S | Q15327 | protein_coding | tolerated(0.22) | benign(0.001) | TCGA-75-5125-01 | Lung | lung adenocarcinoma | Male | Unknown | I/II | Unknown | Unknown | PD | |
ANKRD1 | SNV | Missense_Mutation | c.205N>A | p.Glu69Lys | p.E69K | Q15327 | protein_coding | tolerated(0.18) | benign(0.056) | TCGA-75-6214-01 | Lung | lung adenocarcinoma | Female | Unknown | III/IV | Unknown | Unknown | PD | |
ANKRD1 | SNV | Missense_Mutation | rs768116191 | c.703G>A | p.Ala235Thr | p.A235T | Q15327 | protein_coding | tolerated(0.05) | possibly_damaging(0.8) | TCGA-60-2714-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Chemotherapy | taxol | SD |
ANKRD1 | SNV | Missense_Mutation | rs145387010 | c.368N>T | p.Thr123Met | p.T123M | Q15327 | protein_coding | tolerated(0.35) | benign(0.01) | TCGA-CQ-7068-01 | Oral cavity | head & neck squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
ANKRD1 | SNV | Missense_Mutation | novel | c.545G>T | p.Arg182Leu | p.R182L | Q15327 | protein_coding | deleterious(0.01) | possibly_damaging(0.73) | TCGA-VP-A872-01 | Prostate | prostate adenocarcinoma | Male | <65 | 8 | Unknown | Unknown | SD |
ANKRD1 | SNV | Missense_Mutation | c.416T>A | p.Phe139Tyr | p.F139Y | Q15327 | protein_coding | tolerated(1) | benign(0.019) | TCGA-B7-5818-01 | Stomach | stomach adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
ANKRD1 | SNV | Missense_Mutation | c.644N>A | p.Arg215Gln | p.R215Q | Q15327 | protein_coding | tolerated(0.14) | benign(0.384) | TCGA-BR-8680-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | CR | |
ANKRD1 | SNV | Missense_Mutation | c.785T>C | p.Leu262Pro | p.L262P | Q15327 | protein_coding | tolerated(0.09) | probably_damaging(0.996) | TCGA-CD-A4MG-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |